Navigation Links
Comparative Study Shows Significant Bone In-growth and Advanced Clinical Outcomes Using Zimmer's Trabecular Metal(TM) Technology
Date:2/25/2009

by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. These risks and uncertainties include, but are not limited to, our compliance with the Deferred Prosecution Agreement through March 2009 and the Corporate Integrity Agreement through 2012; the impact of our enhanced healthcare compliance global initiatives and business practices on our relationships with customers and consultants, our market share and our overall financial performance; the success of our quality initiatives; the outcome of the informal investigation by the U.S. Securities and Exchange Commission into Foreign Corrupt Practices Act matters announced in October 2007; price and product competition; changes in customer demand for our products and services caused by demographic changes or other factors; dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials and products; control of costs and expenses; our ability to obtain and maintain adequate intellectual property protection; our ability to successfully integrate acquired businesses; our ability to form and implement alliances; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration and foreign government regulators and tax obligations and risks; the impact of temporarily suspending U.S. distribution of one of our key hip replacement products; product liability an
'/>"/>

SOURCE Zimmer Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
2. New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions
3. Childrens Hospital Receives $6.7 Million Grant From Gates Foundation to Study Influenza Vaccine in Pregnant Women in Asia
4. MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
5. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
6. Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
7. 10-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs
8. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
9. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
10. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
11. Hope for 14 Million Rosacea Sufferers: Pyratine-XR(TM) Study to be Presented at South Beach Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 21, 2014 Influenza will affect as many ... the United States as high as ... to spread is from person to person in respiratory droplets ... serve way of death, but kills much fewer people each ... done by human fluids including sweat, saliva, blood and other ...
(Date:10/22/2014)... Va. and AUSTIN, Texas ... Inc. and PureMHC LLC today announced they have ... develop novel antibody-based immunotherapies designed to target cancers. ... of phosphorylated peptides displayed on the surfaces of ... phosphopeptide tumor targets (PTTs), derived from proteins that ...
(Date:10/22/2014)... Mass. and SHANGHAI , ... (NASDAQ: FMI ) and WuXi PharmaTech ... a collaboration to offer Foundation Medicine,s comprehensive genomic profiling ... China . Under the terms ... WuXi to perform the laboratory component of Foundation Medicine,s ...
Breaking Medicine Technology:WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5
... , Event to Highlight Progress in Research, Advocacy and New Treatments , ... WASHINGTON , May 11 The National Organization for ... that have brought innovative new treatments to market for rare diseases at the 2010 NORD ... on Tuesday, May 18 . , , ...
... U.S. Food and Drug Administration recently approved an application that permits B. Braun ... Injection USP and Dextrose Injection USP in B. Braun,s DUPLEX® Drug Delivery System ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO ) ... Used in hospitals and healthcare centers ...
Cached Medicine Technology:NORD to Honor Rare Disease Innovators 2NORD to Honor Rare Disease Innovators 3NORD to Honor Rare Disease Innovators 4FDA Approves Cefepime for Use In B. Braun's DUPLEX(R) System 2FDA Approves Cefepime for Use In B. Braun's DUPLEX(R) System 3
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
(Date:10/22/2014)... WALTHAM, MA (PRWEB) October 22, 2014 ... developing new solutions for the treatment of bacterial infections, ... J. Sinskey has joined its board of directors. ... Microbiology and Engineering Systems at The Massachusetts Institute of ... the MIT faculty since 1968. Dr. Sinskey also holds ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... are only about half as likely as white women to ... indicates, and the racial disparity persists even when donor eggs ... white patients became pregnant after IVF, compared to about 17 ... cycles over two years to tease out the impact of ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter , ... young adult men may lead to increased blood pressure, according ... a similar rise in blood pressure for young adult women ... young adult women drank lightly or moderately, their risk of ... "This finding parallels studies in older adult men and ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- Measures taken ... plantation in Ebola-ravaged Liberia may have limited the spread ... researchers report. The Firestone Natural Rubber Co. provides ... and residents of nearby densely populated communities. Between ... and suspected Ebola cases among those 80,000 people. That ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... Blanket Limbo to raise funds for amputees DALLAS, Feb. 18 ... arm or a leg. Of those impacted, many find themselves with ... limbs needed to resume their daily lives. , ... awareness to the plight of these amputees and provide them with ...
... save lives by donating blood regularlySEWELL, N.J., Feb. 18 ... February 21, 2009 from 9:00 a.m. to 3:00 p.m. ... To make an immediate appointment for this blood ... )Koerner is battling a type of cancer called Acute ...
... 18 The ,Help is Here Express, bus tour ... February 23-27 at various cities throughout the state ... information on programs that provide prescription medicines for free ... having risen for seven straight months, standing today at ...
... widely used blood pressure medication may be the key ... according to a newly published study by researchers at ... offer the hope of an improved quality of life ... study drew on a hypothesis from previous studies that ...
... Ill., and Osaka, Japan, February 13, 2009 Takeda ... North America, Inc., announced today that the United States ... 40 mg and 80 mg for the chronic management ... medication is the first new treatment option in more ...
... clinicians and researchers in the bone health field ... held from March 18-21 in Athens, Greece. ... four-day meeting which will feature an expanded scientific ... clinically-oriented ,Meet-the-Professor, sessions. The programme is also enhanced ...
Cached Medicine News:Health News:Limbs for Life Foundation to Host 8th Annual Fundraiser and Live Auction 2Health News:Blood Drive Held in Honor of Sewell, NJ Resident - Ellie Koerner 2Health News:Partnership for Prescription Assistance Prepared to Help Texas Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Texas Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Texas Workers Hurt by Recession 4Health News:Blood pressure compound may benefit brain tumor patients 2Health News:Blood pressure compound may benefit brain tumor patients 3Health News:FDA approves ULORIC (febuxostat) for the chronic management of hyperuricemia in patients with gout 2Health News:FDA approves ULORIC (febuxostat) for the chronic management of hyperuricemia in patients with gout 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: